Hematologic Cancers

The US Food and Drug Administration (FDA) approved carfilzomib (Kyprolis; Onyx Pharmaceuticals, Inc.) for the treatment of patients with multiple myeloma who have received at least 2 prior therapies and who have demonstrated disease progression. Read More ›

Chronic myeloid leukemia (CML) is a clonal proliferative disorder of the hematopoietic cells of myeloid lineage1-3 driven by a reciprocal translocation between chromosomes 9 and 22, resulting in the so-called Philadelphia (Ph) chromosome. Read More ›

Many patients with multiple myeloma succumb to infection before they have a chance to benefit from cancer therapy, according to a new study from Sweden. Read More ›

In August 2012, vincristine sulfate LIPOSOME injection (VSLI) (Marqibo) was granted accelerated approval by the US Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after 2 or more regimens. Read More ›

The management of relapsed/ refractory acute lymphoblastic leukemia (ALL) is a vexing problem and requires extensive, aggressive supportive care throughout the course of therapy, explained Joseph C. Alvarnas, MD, City of Hope Comp­rehensive Cancer Center, Duarte, Cali­fornia, in a presentation at the National Com­prehensive Cancer Network (NCCN) 7th Annual Congress on Hematologic Malignancies. Read More ›



At 5 years of follow-up of the VISTA trial, the combination of bortezomib plus melphalan and prednisone (VMP) demonstrated a survival advantage over MP alone as up-front treatment of patients with multiple myeloma who were not transplant candidates. At a median followup of 60.1 months, the absolute difference in overall survival (OS) between the treatment arms was 13 months, according to final results presented at the 53rd Annual Meeting of the American Society of Hematology. Read More ›


The best strategy for management of low-tumor-burden follicular lymphoma (FL) following response to induction therapy is controversial. The phase 3 RESORT study compared maintenance rituximab therapy versus rituximab retreatment at disease progression, and results suggest that retreatment is the preferred approach. The study was presented at the 53rd Annual Meeting of the American Society of Hematology.

Read More ›


Page 7 of 10


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: